未登录

A

Artur Beberok

department of pharmaceutical chemistry

H指数:23

被引数:1,715

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluation of Drug-Associated Phototoxicity Under 980 nm Near-Infrared Laser Irradiation in Human Dermal Fibroblasts

在980 nm近红外激光照射下对人真皮成纤维细胞的药物相关光毒性评价

IF5.5

2026-10-060

OA

MIM1 – a selective Mcl-1 protein inhibitor augments the proapoptotic activity of moxifloxacin toward MDA-MB-231 triple-negative breast cancer cells – a preliminary in vitro study

MIM1——一种选择性Mcl-1蛋白抑制剂，增强了moxifloxacin对MDA-MB-231三阴性乳腺癌细胞的促凋亡活性——一项初步体外研究

Pharmacological Reports

IF3.8

2025-09-020

OAAI

Moxifloxacin and BH3 Mimetic-MIM1 Demonstrate a Potential Synergistic Anti-Melanoma Mode of Action by Cytotoxic and Proapoptotic Activity Enhancement in A375 and G361 Melanoma Cells

莫西沙星和BH3拟似物-MIM1通过增强细胞毒性及促凋亡活性，在A375和G361黑色素瘤细胞中表现出潜在的协同抗黑色素瘤作用机制。

IF0

2025-08-050

OA

Comparison of Micelles Single- and Dual-Targeted with Folic Acid and Biotin as the Delivery System of Docetaxel─The Influence of the Type and Amount of the Ligand on Morphology; Physicochemical Properties; and Cytotoxicity

叶酸和生物素靶向的胶束单药和双药靶向作为多西他赛递送系统─配体类型和数量对形态、物理化学性质和细胞毒性的影响

Molecular Pharmaceutics

IF4.5

2025-06-260

PRE

Effect of prophylactic doses of enoxaparin on antifactor Xa activity confirmed by rotational thromboelastometry in critically ill patients: a preliminary prospective cohort study

磺达肝癸钠预防剂量对危重患者抗凝血因子Xa活性的影响：一项初步前瞻性队列研究（通过旋转血栓弹力图证实）

FRONTIERS IN PHARMACOLOGY

IF4.8

2025-01-150

OA

Comparison of PLLA-PEG and PDLLA-PEG micelles for co-encapsulation of docetaxel and resveratrol

Plla-peg和pdlla-peg胶束共包封多西他赛和白藜芦醇的比较

JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS

IF3.4

2023-08-312

OA

The effect of sulindac on redox homeostasis and apoptosis-related proteins in melanotic and amelanotic cells

PHARMACOLOGICAL REPORTS

IF3.8

2023-05-172

OAAI

Design, Synthesis and Biological Evaluation of Quinoline-8-Sulfonamides as Inhibitors of the Tumor Cell-Specific M2 Isoform of Pyruvate Kinase: Preliminary Study

IF4.6

2023-03-094

OAAI

Evaluation of Possible Neobavaisoflavone Chemosensitizing Properties towards Doxorubicin and Etoposide in SW1783 Anaplastic Astrocytoma Cells

IF5.2

2023-02-120

OAAI

Interaction between moxifloxacin and Mcl-1 and MITF proteins: the effect on growth inhibition and apoptosis in MDA-MB-231 human triple-negative breast cancer cells

PHARMACOLOGICAL REPORTS

IF3.8

2022-09-012

OAAI

Nanoparticles Loaded with Docetaxel and Resveratrol as an Advanced Tool for Cancer Therapy

IF3.9

2022-05-2035

OAAI

The Biochemical and Molecular Analysis of Changes in Melanogenesis Induced by UVA-Activated Fluoroquinolones-In Vitro Study on Human Normal Melanocytes

IF5.2

2021-10-274

OAAI

Neobavaisoflavone May Modulate the Activity of Topoisomerase Inhibitors towards U-87 MG Cells: An In Vitro Study

IF4.6

2021-07-275

OAAI

The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)-preliminary molecular docking analysis

PHARMACOLOGICAL REPORTS

IF3.8

2021-05-306

OAAI

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

用于抗癌药物递送的叶酸和生物素的单靶向和双靶向纳米颗粒

IF5.5

2021-03-0371

OAAI

PARP1 as a Marker of an Aggressive Clinical Phenotype in Cutaneous Melanoma-A Clinical and an In Vitro Study

IF5.2

2021-01-3113

OAAI

Response of Human Glioblastoma Cells to Vitamin B12 Deficiency: A Study Using the Non-Toxic Cobalamin Antagonist

人胶质母细胞瘤细胞对维生素B12缺乏的反应: 使用无毒钴胺素拮抗剂的研究

IF3.5

2021-01-196

OAAI

Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis

PHARMACOLOGICAL REPORTS

IF3.8

2020-10-1554

OAAI

Astrogliosis in an Experimental Model of Hypovitaminosis B12: A Cellular Basis of Neurological Disorders Due to Cobalamin Deficiency

IF5.2

2020-10-097

OAAI

Cobalamin Deficiency: Effect on Homeostasis of Cultured Human Astrocytes

IF5.2

2019-11-249

OAAI